Please use this identifier to cite or link to this item:
Title: A review of the International Early Recommendations for Departments Organization and Cancer Management Priorities during the Global COVID-19 Pandemic. Applicability in Low- and Middle-Income Countries
Authors: Belkacemi, Yazid
Grellier, Noemie
Ghith, Sahar
Debbi, Kamel
Coraggio, Gabriele
Bounedjar, Adda
Samlali, Redouane
Tsoutsou, Pauletta G.
Ozsahin, Mahmut
Chauvet, Marie-Pierre
Turkan, Sedat
Boussen, Hamouda
Kuten, Abraham
Tesanovic, Dusanka
Errihani, Hassan
Benna, Farouk
Bouzid, Kamel
Idbaih, Ahmed
Mokhtari, Karima
Popovic, Lazar
Spano, Jean-Philippe
Lotz, Jean-Pierre
Cherif, Aziz
To, Hahn
Kovcin, Vladimir
Arsovski, Oliver
Beslija, Semir
Dzodic, Radan
Markovic, Ivan
Vasovic, Suzana
Stamatovic, Liljana
Radosavljevic, Davorin
Radulovic, Sinisa
Vrbanec, Damir
Sahraoui, Souha
Vasev, Nino
Stojkovski, Igor 
Risteski, Milan
Freixa, Salvador Villà
Krengli, Marco
Radosevic, Nina
Mustacchi, Giorgio
Filipovic, Mladen
Kerrou, Khaldoun
Taghian, Alphonse G.
Todorovic, Vladimir
Geara, Fady
Gligorov, Joseph
Keywords: COVID-19
Issue Date: Jun-2020
Publisher: Elsevier BV
Journal: European Journal of Cancer
Abstract: Coronavirus disease 2019 (COVID-19) is an infectious disease caused by a new virus that has never been identified in humans before. COVID-19 caused at the time of writing of this article, 2.5 million cases of infections in 193 countries with 165,000 deaths, including two-third in Europe. In this context, Oncology Departments of the affected countries had to adapt quickly their health system care and establish new organizations and priorities. Thus, numerous recommendations and therapeutic options have been reported to optimize therapy delivery to patients with chronic disease and cancer. Obviously, while these cancer care recommendations are immediately applicable in Europe, they may not be applicable in certain emerging and low and middle income countries (LMICs). In this review we aimed to summarize these international guidelines according to cancer types, making a synthesis for daily practice to protect patients, staff and tailor anti-cancer therapy delivery taking into account patients/tumor criteria and tools availability. Thus, we will discuss their applicability in the LMICs with different organizations, limited means and different constraints
DOI: 10.1016/j.ejca.2020.05.015
Appears in Collections:Faculty of Medicine: Journal Articles

Show full item record

Page view(s)

checked on Nov 28, 2020

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.